Publications

Evaluation of Daptomycin Activity Tested against 35,058 Bacterial Strains from Hospitalized Patients: Summary of a 7 Year Surveillance Program for North America (2002-2008), Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Activity of Telavancin and Comparator Agents Tested against Gram-Positive Isolates Cultured from Skin and Skin Structure Infections, Lead author: Mendes RE, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Contemporary Antimicrobial Activity of CEM-102 (Fusidic Acid) Against Canadian Isolates of Staphylococci and Streptococci (2001-2006), Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Update on Spectrum of CEM-102 (Fusidic Acid) Against Contemporary Wildtype Bacterial Species Including Mutational Resistance Analysis, and Synergy Testing, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Oritavancin Activity tested against Resistant Subsets of Gram-Positive Pathogens, Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Telavancin Activity Tested Against Gram-Positive Pathogens Responsible for Bloodstream Infections Collected during a Global Surveillance Program (2007-2008), Lead author: Mendes RE, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

CEM-101, A novel fluoroketolide: Activity against recent (2008) isolates of multidrug-resistant S. pneumoniae, Lead author: Jones RN, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Antimicrobial Susceptibility of a Worldwide Collection of Stenotrophomonas maltophilia Tested Against Tigecycline and Agents Used for S. maltophilia Infections, Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Comprehensive investigations of piperacillin/tazobactam (P/T) generic formulations compared to branded lots: Studies of 46 lots from 29 manufacturers, Lead author: Moet G, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Validity of CLSI Disk Diffusion Zone Correlates for Enterobacteriaceae versus Older cephalosporins, Lead author: Badal, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Pilot studies to guide CLSI re-evaluations of S. pneumoniae and ß-haemolytic streptococcal disk diffusion criteria for commonly used penicillins and cephalosporins, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Performance of CEM-102 (Fusidic Acid) Susceptibility Testing Reagents; Broth Microdilution, Disk Diffusion and Etest Methods, Lead author: Rhomberg PR, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

In Vitro Activity of Ceftaroline Tested Against Recent Clinical Isolates from the United States (USA), Lead author: Sader HS, presented at 47th annual Infectious Diseases Society of America (IDSA), October 29 – November 1, 2009, Philadelphia, PA

Relevance of Protein Binding of CEM-102 (Fusidic acid) and its pH-dependent Effect on In Vitro Activity, Lead author: Degenhardt, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Pharmacokinetics-Pharmacodynamics (PK-PD) of CEM-102 against Methicillin-Resistant Staphylococcus aureus (MRSA) Using an In Vitro PD Model and Mechanism-Based Modeling, Lead author: Tsuji, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Telavancin Spectrum of Activity against Staphylococcus spp. Recovered from European Hospitals (2007-2008), Lead author: Mendes RE, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Kinetic Characterization of Novel Chromosome-Encoded CTX-M-78 from a Kluyvera spp. Clinical Isolate also Carrying a Plasmid-Borne Class 1 Integron, Lead author: Gutkind, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Emergence of MLS_B L-phenotype and lnu(B) resistance in Streptococcus agalactiae in Asia Pacific, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Linezolid Resistance Mechanisms among Non-susceptible Staphylococcus spp. and Enterococcus spp. Pathogens Collected from Global Surveillance Programs (2001-2008), Lead author: Mendes RE, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Ceftaroline Activity against Staphylococci and Characterization of S. aureus with Elevated Ceftaroline MIC Values: Results from the Ceftaroline Program, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Low CEM-102 (Fusidic Acid) Resistance Rates and High Prevalence of Acquired Genes Among Staphylococcus spp. From North America and Australia, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of Tigecycline Tested against a Worldwide Collection of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Susceptibility of Gram-positive Organisms Isolated in Latin American Hospitals: Evaluation of the Emergence and Dissemination of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Susceptibility Pattern of Gram-positive Organisms Isolated in Australian Medical Centers (2004, 2006-2007): Results from a Multi-Center Prospective Surveillance Program, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Decreasing Susceptibility Rates Among Acinetobacter spp. Clinical Isolates Collected Worldwide (2005-2008), Lead author: Mendes RE, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Emergence of bla_OXA-48 among Enterobacter cloacae in Argentina and its Prevalence among Carbapenem Non-Susceptible Enterobacteriaceae, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Emergence of OXA-48 Carbapenemases among Klebsiella spp. from India, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

High Prevalence of CTX-M-Producing Isolates and Emergence of KPC-Encoding Genes in the Western United States, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Diversity of Acquired Ribosomal RNA Methylase Genes Encoding Aminoglycoside Resistance in the Asia-Pacific Region, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Recommended Ulifloxacin MIC Quality Control Ranges for Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Streit J, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Initial Quality Control Ranges for CEM-102 (Fusidic Acid) Using the CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Recently Approved Tigecycline Susceptibility Breakpoints for S. pneumoniae and H. influenzae: Do Broth Microdilution and Disk Diffusion Results Agree?, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Minocycline Using Gram-Positive and Gram-Negative Organisms, Lead author: Knapp C, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Epidemiologic Detection Of Carbapenemase-producing Klebsiella spp. By EUCAST or CLSI Clinical Breakpoints, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Iclaprim Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Bastulli, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Susceptibility System to the CLSI Broth Microdilution Method for Telavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Holliday, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of Ceftaroline against Emerging Serotypes of Streptococcus pneumoniae, Lead author: Jacobs, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Streptococci from United States and European Medical Centers: Results from the Ceftaroline Longitudinal Assessment of Spectrum and Susceptibility (CLASS) Program, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride Compound : A Gram-negative Antimicrobial, Lead author: Alley, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Spectrum and Activity of Ceftaroline Combined with NXL-104 Tested against a Challenge Collection of Pathogens with Well Characterized Resistances, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Clinical Outcomes of Infections Caused by Extended-Spectrum &#223-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility, Lead author: Le, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections, Lead author: Hogan, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA